Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.

NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.

New Jersey Senate Bill 3098 would require health insurance plans to cover biomarker testing for the diagnosis, treatment, and management of a patient's disease.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...

SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.